Sign in5 stories
The Nasdaq-listed regenerative medicine company sold stock and warrants at $4.08 per share, while disclosing an unpaid $10 million milestone payment owed to BioTissue Holdings.
SEC filing
BioStem Technologies filed an S-1 covering resale of up to 12,050,000 shares tied to a new equity purchase deal with Roth Principal Investments, alongside a Form D notice of the same offering.
SEC filing (2)
The Pompano Beach regenerative medicine company can sell shares to Roth Principal Investments over time, subject to a registration statement and price conditions.
SEC filing
BioStem reported $7.9 million in second-quarter revenue, raised full-year guidance, and uplisted to the Nasdaq Capital Market on August 7, 2026.
SEC filing
The Florida-based tissue allograft maker disclosed going-concern doubt tied to CMS reimbursement cuts, BioTissue-related obligations, and an existing loan.
SEC filing